Argonaute RNA Ltd filed a Form D with the Securities and Exchange Commission on 2026-09-24.
Argonaute RNA Ltd filed a Form D notice of an exempt securities offering with the SEC on September 24, 2026. The filing reports $1.80M sold. Its industry group is Biotechnology. It names Anthony Parker (Executive Officer, Director), Michael Khan (Executive Officer, Director), Richard Tompkins (Director) (SEC Form D, September 24, 2026).
Argonaute RNA Ltd raised on Sep 24. 125 companies raised this week.
Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.
| Andersen Aggregator LLC | $1.9B | Business services |
| AT Umbrella LLC | $1.9B | Business services |
| Legora, Inc. | $221M | AI and software |
| MD INVESTMENT LLC | $169M | Business services |
| Serval Inc. | $149M | AI and software |
Selling to Argonaute RNA Ltd? See who runs it and how to reach them, plus this week's 25 other newly funded companies.
Is this your company?
Sell to companies like Argonaute RNA Ltd? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-09-24 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Argonaute RNA Ltd.
Free to see. No signup.
More on the people and the money behind Argonaute RNA Ltd, from the filings we hold.
Biotechnology raises by companies based in the United Kingdom, filed in September 2026, largest first.
Get an email when Argonaute RNA Ltd files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Argonaute RNA Ltd raises, hires or launches. No email unless you switch it on.
Watch Argonaute RNA Ltd →Get the full cited report on Argonaute RNA Ltd
What the filing shows about Argonaute RNA Ltd
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Argonaute RNA Ltd: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Argonaute RNA Ltd's address as Cardiff Business Technology Centre, Senghennydd Road, Cardiff, X0 CF24 4AY.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Argonaute RNA Ltd is a registered filer with the SEC (CIK 2157150) and has filed since 2026-09-24. 1 filing is on record, the latest on 2026-09-24.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Argonaute RNA Ltd's Form D of 2026-09-24 names Anthony Parker, Michael Khan, Richard Tompkins and 6 more as its officers, directors or promoters.
Its new offerings report $1.80M sold across 1 offering, as its own filings state.
Trailing twelve months. 771 filings in Biotechnology, totalled by week. The dot is this raise, $1.80M, on the same scale — one filing against the whole group's total, so it sits low by construction.
Checked away from the filing. What is below does not come from the record on sec.gov.
Developing safe and reliable methods of temporarily silencing target genes in different tissue cells.
The title and description the site itself served, answering 200. Not a cached copy and not the company's directory entry — what was live when we asked.
Anthony Parker is named as Executive Officer and Director on the Form D that Argonaute RNA Ltd filed with the SEC on 24 September 2026, one of 9 people that filing names.
Michael Khan is named as Executive Officer and Director on the Form D that Argonaute RNA Ltd filed with the SEC on 24 September 2026, one of 9 people that filing names.
Richard Tompkins is named as Director on the Form D that Argonaute RNA Ltd filed with the SEC on 24 September 2026, one of 9 people that filing names.
Johnathan Matlock is named as Director on the Form D that Argonaute RNA Ltd filed with the SEC on 24 September 2026, one of 9 people that filing names.
David Ball is named as Director on the Form D that Argonaute RNA Ltd filed with the SEC on 24 September 2026, one of 9 people that filing names.
Alexander Fink is named as Director on the Form D that Argonaute RNA Ltd filed with the SEC on 24 September 2026, one of 9 people that filing names.
Ross Burn is named as Director on the Form D that Argonaute RNA Ltd filed with the SEC on 24 September 2026, one of 9 people that filing names.
Nabil Al-Chalaby is named as Director on the Form D that Argonaute RNA Ltd filed with the SEC on 24 September 2026, one of 9 people that filing names.
Nigel Davis is named as Director on the Form D that Argonaute RNA Ltd filed with the SEC on 24 September 2026, one of 9 people that filing names.
9 people named on the filing — 2 holding an executive role and 7 as directors only.
Named as of the 2026-09-24 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Argonaute RNA Ltd
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Argonaute RNA Ltd: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Argonaute RNA Ltd covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Argonaute RNA LtdYou get an alert in MentionFox the next time this company shows up.
If you're behind Argonaute RNA Ltd: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov, and from the company's own site, read directly on 2026-09-26 (argonauterna.com).
Each opens in a new tab, filled in for Argonaute RNA Ltd. With no account yet, you sign up free and land on the result.
On these lists: Outside the US raises, week of 2026-09-21 · Biotech raises, week of 2026-09-21
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/argonaute-rna-ltd-form-d-000001